Danaher (NYSE:DHR)‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research report issued on Wednesday, Marketbeat.com reports. They presently have a $141.00 price target on the conglomerate’s stock, up from their prior price target of $138.00. Needham & Company LLC’s price objective would suggest a potential upside of 11.51% from the stock’s previous close.
DHR has been the subject of several other reports. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $140.00 price target on shares of Danaher in a research note on Monday, March 4th. Zacks Investment Research raised Danaher from a “hold” rating to a “buy” rating and set a $147.00 target price on the stock in a report on Tuesday, April 9th. Janney Montgomery Scott raised Danaher from a “neutral” rating to a “buy” rating in a report on Monday, February 25th. Cowen reaffirmed a “buy” rating and set a $110.00 target price on shares of Danaher in a report on Monday, January 7th. Finally, UBS Group increased their target price on Danaher from $125.00 to $144.00 and gave the stock a “buy” rating in a report on Tuesday, February 26th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $129.14.
Shares of Danaher stock traded up $1.56 during trading on Wednesday, hitting $126.45. The company’s stock had a trading volume of 1,201,519 shares, compared to its average volume of 2,944,550. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.47 and a quick ratio of 1.07. The firm has a market cap of $91.74 billion, a price-to-earnings ratio of 27.97, a PEG ratio of 2.39 and a beta of 1.04. Danaher has a 52 week low of $94.59 and a 52 week high of $134.50.
In related news, insider Rainer Blair sold 37,859 shares of the business’s stock in a transaction on Wednesday, February 27th. The shares were sold at an average price of $127.45, for a total value of $4,825,129.55. Following the sale, the insider now owns 32,661 shares in the company, valued at $4,162,644.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Robert S. Lutz sold 15,000 shares of the business’s stock in a transaction on Sunday, February 24th. The stock was sold at an average price of $127.00, for a total transaction of $1,905,000.00. Following the completion of the sale, the chief accounting officer now owns 22,251 shares in the company, valued at approximately $2,825,877. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 183,150 shares of company stock valued at $23,279,637. Corporate insiders own 11.40% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Laurel Wealth Advisors LLC bought a new position in shares of Danaher during the 4th quarter valued at $27,000. CX Institutional increased its position in Danaher by 188.7% in the 1st quarter. CX Institutional now owns 205 shares of the conglomerate’s stock valued at $27,000 after acquiring an additional 134 shares during the period. Hanson McClain Inc. increased its position in Danaher by 852.9% in the 4th quarter. Hanson McClain Inc. now owns 324 shares of the conglomerate’s stock valued at $33,000 after acquiring an additional 290 shares during the period. Executive Wealth Management LLC acquired a new stake in Danaher in the 4th quarter valued at approximately $39,000. Finally, Ruggie Capital Group acquired a new stake in Danaher in the 4th quarter valued at approximately $40,000. Institutional investors own 77.59% of the company’s stock.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
See Also: Dividend Achievers
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.